The European Commission has granted orphan drug designation to ILB, Tikomed‘s investigational treatment for amyotrophic lateral sclerosis (ALS). In the EU, this designation is based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP), a part of the European…
ILB, Potential ALS Therapy in Phase 2 Trial,Named Orphan Drug in Europe
The U.S. Food and Drug Administration has granted Prosetin orphan drug designation for the treatment of amyotrophic lateral sclerosis (ALS). Orphan drug designation grants financial incentives to companies developing medications for rare diseases, which might not be profitable enough to pursue without government assistance. While a Phase…
In his book “Out of Solitude,” Henri Nouwen writes, “When we honestly ask ourselves which persons in our lives mean the most to us, we often find that it is those who, instead of giving advice, solutions, or cures, have chosen rather to share our pain and touch…
Pharnext’s investigational oral combination therapy PXT864 prevents degeneration of motor neurons and their point of contact with muscle cells, as well as the buildup of toxic TDP-43 protein aggregates — all hallmarks of amyotrophic lateral sclerosis (ALS) — in cellular models of the disease. The data…
Just like Lionel Barrymore as James Temple in “Key Largo“ and Gary Sinise as Lt. Dan Taylor in “Forrest Gump,” I survived a hurricane wheelchair-bound. Unlike the original works that those two movies are derived from, my hurricane…
Accessing and understanding insurance coverage, and paying for medical treatments and services top the list of stressors that burden people with amyotrophic lateral sclerosis (ALS) in the United States, a survey of patients and caregivers reports. Ten percent of its 444 respondents — in 1 in every 10 —…
Recently, I noticed I was having problems keeping track of time. Not clock time, as in being a little early or showing up too late. But calendar time — the past weeks and months of living in lockdown have caused my days to morph together. I knew I was doing…
A new telehealth app to help people with motor neuron diseases such as amyotrophic lateral sclerosis (ALS) connect with their healthcare providers during the COVID-19 pandemic has been fast-tracked for use in the United Kingdom. The Telehealth in Motor Neurone Disease (TiM) system, developed by the …
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…
Two U.K. organizations, the Motor Neurone Disease (MND) Association and Nick Smith Foundation, are partnering on a pilot project to help youngsters affected by motor neurone disease (MND) create memories of their family member or friend. The initiative is being tested in four cities in England: Milton Keynes, Manchester,…
Recent Posts
- Grant funds new ALS treatment approach targeting TDP-43 pathway
- Amydis awarded $2.5M to develop diagnostic eye test for ALS
- Mourning the loss of a leader, friend, and advocate for women with ALS
- Developer to test ALS therapy with help of Mass General’s MyMatch
- A story of a family’s loss offers guidance amid my grief with ALS